56.50
price up icon1.47%   0.82
pre-market  Vorhandelsmarkt:  56.50  
loading
Schlusskurs vom Vortag:
$55.68
Offen:
$55.61
24-Stunden-Volumen:
859.18K
Relative Volume:
1.03
Marktkapitalisierung:
$3.17B
Einnahmen:
$665.13M
Nettoeinkommen (Verlust:
$64.50M
KGV:
49.38
EPS:
1.1442
Netto-Cashflow:
$185.87M
1W Leistung:
+8.61%
1M Leistung:
+18.70%
6M Leistung:
+73.90%
1J Leistung:
+62.03%
1-Tages-Spanne:
Value
$55.02
$57.65
1-Wochen-Bereich:
Value
$51.84
$57.65
52-Wochen-Spanne:
Value
$29.16
$57.65

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name
Firmenname
Supernus Pharmaceuticals Inc
Name
Telefon
301-838-2500
Name
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Name
Mitarbeiter
674
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
SUPN's Discussions on Twitter

Vergleichen Sie SUPN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
SUPN
Supernus Pharmaceuticals Inc
56.50 3.12B 665.13M 64.50M 185.87M 1.1442
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
144.10 63.79B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.23 43.49B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.18 40.30B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.03 23.21B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
453.53 20.59B 3.08B 1.24B 1.07B 25.61

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-09 Hochstufung Piper Sandler Neutral → Overweight
2025-07-30 Hochstufung Cantor Fitzgerald Neutral → Overweight
2025-02-19 Herabstufung Cantor Fitzgerald Overweight → Neutral
2025-01-06 Eingeleitet Cantor Fitzgerald Overweight
2024-09-11 Herabstufung Piper Sandler Overweight → Neutral
2023-01-03 Fortgesetzt Jefferies Buy
2021-12-01 Fortgesetzt Jefferies Buy
2021-04-13 Hochstufung Jefferies Hold → Buy
2020-06-16 Hochstufung Piper Sandler Neutral → Overweight
2020-06-15 Fortgesetzt Jefferies Hold
2019-11-08 Herabstufung Berenberg Buy → Hold
2019-11-07 Herabstufung Stifel Buy → Hold
2019-11-06 Herabstufung Jefferies Buy → Hold
2018-11-12 Bestätigt B. Riley FBR Buy
2018-01-18 Bestätigt B. Riley FBR, Inc. Buy
2017-12-28 Bestätigt B. Riley FBR, Inc. Buy
2017-12-04 Hochstufung Janney Neutral → Buy
2017-11-08 Hochstufung Stifel Hold → Buy
2017-10-19 Eingeleitet FBR & Co. Buy
2017-09-19 Herabstufung Stifel Buy → Hold
2017-07-17 Herabstufung Piper Jaffray Overweight → Neutral
2017-07-14 Eingeleitet Janney Neutral
2017-06-01 Hochstufung Piper Jaffray Neutral → Overweight
2016-07-18 Herabstufung Northland Capital Outperform → Market Perform
2016-07-18 Herabstufung Piper Jaffray Overweight → Neutral
2016-02-08 Hochstufung Jefferies Hold → Buy
2015-11-05 Bestätigt Northland Capital Outperform
2015-10-28 Eingeleitet Northland Capital Outperform
Alle ansehen

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

pulisher
12:20 PM

Can Supernus Pharmaceuticals Inc. stock continue upward trendPortfolio Performance Report & Long Hold Capital Preservation Plans - newser.com

12:20 PM
pulisher
Oct 30, 2025

Supernus Pharmaceuticals Hits New 52-Week High of $55.95 - Markets Mojo

Oct 30, 2025
pulisher
Oct 30, 2025

Supernus Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Update & Consistent Profit Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

How to monitor Supernus Pharmaceuticals Inc. with trend dashboardsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Why Supernus Pharmaceuticals Inc. stock remains undervaluedTrade Entry Summary & Safe Capital Allocation Plans - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Long term hold vs stop loss in Supernus Pharmaceuticals Inc.IPO Watch & Risk Controlled Swing Alerts - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Top chart patterns to watch in Supernus Pharmaceuticals Inc.Watch List & Verified Short-Term Plans - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

What institutional flow reveals about Supernus Pharmaceuticals Inc.Treasury Yields & Community Verified Trade Alerts - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals Inc Stock Analysis and ForecastQuarterly Earnings Review & Rapid Portfolio Appreciation - earlytimes.in

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals (SUPN) Gains Market Attention with Key CNS Drugs - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy - sharewise.com

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus a new buy at BofA on 'underappreciated' CNS assets - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? - Yahoo Finance

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals Hits New 52-Week High of $53.28 - Markets Mojo

Oct 29, 2025
pulisher
Oct 29, 2025

BofA Securities Initiates Supernus Pharmaceuticals at Buy With $65 Price Target - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

B of A Securities Initiates Coverage on SUPN with a Buy Rating | - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

B of A Securities Initiates Coverage of Supernus Pharmaceuticals (SUPN) with Buy Recommendation - Nasdaq

Oct 29, 2025
pulisher
Oct 29, 2025

Is Supernus Pharmaceuticals Inc. stock near bottom after decline2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Using data models to predict Supernus Pharmaceuticals Inc. stock movementTrade Analysis Summary & Safe Entry Trade Reports - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

It’s Clear How Big Money Flows Lift Supernus - Yahoo Finance

Oct 29, 2025
pulisher
Oct 28, 2025

Will Supernus Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 Selloffs & Safe Entry Point Alerts - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Supernus Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Investment Summary & Smart Swing Trading Alerts - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 27, 2025

Is Supernus Pharmaceuticals Inc. stock attractive after correctionEntry Point & Low Drawdown Trading Strategies - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Advanced analytics toolkit walkthrough for Supernus Pharmaceuticals Inc.2025 Year in Review & Daily Profit Maximizing Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - sharewise.com

Oct 27, 2025
pulisher
Oct 27, 2025

Sentiment analysis tools applied to Supernus Pharmaceuticals Inc.2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How Supernus Pharmaceuticals Inc. stock reacts to Fed rate cutsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com

Oct 27, 2025

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$44.06
price down icon 5.51%
$22.57
price down icon 0.09%
drug_manufacturers_specialty_generic RDY
$13.45
price up icon 0.30%
$10.36
price up icon 0.88%
$138.04
price up icon 0.01%
$453.53
price down icon 0.39%
Kapitalisierung:     |  Volumen (24h):